Develops cell engineering technologies for cell and gene therapies.
Jun 2026Revenue $31.1M/yrExpenses $72.8M/yr
No trendCash runway ≈ 4.5 years from Jun 2026
Figures by year
When will Maxcyte be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $31.1M and expenses $72.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $33.0M | $84.9M | −$51.9M |
| Dec 2024 | $38.6M | $89.8M | −$51.2M |
| Dec 2023 | $41.3M | $89.6M | −$48.3M |
| Dec 2022 | $44.3M | $71.6M | −$27.4M |
| Dec 2021 | $33.9M | $52.1M | −$18.2M |
| Dec 2020 | $26.2M | $37.2M | −$11.1M |
| Dec 2019 | $21.6M | $34.0M | −$12.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.